✦ LIBER ✦

An “all-oral” combination therapy in chronic lymphocytic leukemia including the oral ldarubicin

✍ Scribed by Stefano Molica; Domenico Levato; Nicola Di Renzo; Antonio La Sala; Mario Carotenuto

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 252 KB
Volume: 52
Category: Article
ISSN: 0361-8609
DOI: 10.1002/1096-8652(199607)52:3<235::aid-ajh2830520305>3.0.co;2-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An “all-oral” combination therapy in chr

An “all-oral” combination therapy in chronic lymphocytic leukemia including the oral idarubicin

✍ Molica, Stefano; Levato, Domenico; Di Renzo, Nicola; La Sala, Antonio; Carotenut 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 252 KB

A comparison of the efficacy and safety

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial

✍ Claire E. Dearden; Sue Richards; Monica Else; Daniel Catovsky; Peter Hillmen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB

## Abstract ## BACKGROUND: An oral formulation of fludarabine was introduced for use in chronic lymphocytic leukemia in 2001 following studies demonstrating the bioequivalence of a 40 mg/m^2^ oral dose with a 25 mg/m^2^ intravenous dose. We assessed retrospectively the efficacy of these two routes

Activity of cladribine combined with cyc

Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion : Report From the Polish Adult Leukemia Group

✍ Tadeusz Robak; Jerzy Z. Blonski; Ewa Wawrzyniak; Joanna Gora-Tybor; Aleksandra P 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

Combination therapy with fludarabine and

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : A phase 2 trial of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Elizabeth R. Vazquez; David R. Spigel; Eric Raefsky; James D 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 2 views

## Abstract ## BACKGROUND The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first‐line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ## METHO

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH